Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen

Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen

Abstract The clinical translation of theranostic 177Lu-radiopharmaceuticals based on inhibitors of the prostate-specific membrane antigen (PSMA) has demonstrated positive clinical responses in patients with advanced prostate cancer (PCa). However, challenges still remain, particularly regarding thei...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Debora Carpanese, Guillermina Ferro-Flores, Blanca Ocampo-Garcia, Clara Santos-Cuevas, Nicola Salvarese, Mariangela Figini, Giulio Fracasso, Laura De Nardo, Cristina Bolzati, Antonio Rosato, Laura Meléndez-Alafort
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/9b2d1ad6b66740dab5e3f6564255938b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares